OptiBiotix Health Plc (LON:OPTI – Get Free Report)’s stock price reached a new 52-week low during trading on Friday. The company traded as low as GBX 4.50 and last traded at GBX 4.55, with a volume of 168,245 shares trading hands. The stock had previously closed at GBX 4.55.
OptiBiotix Health Stock Performance
The stock has a market capitalization of £4.70 million, a price-to-earnings ratio of -1.08 and a beta of 1.82. The stock has a 50-day moving average price of GBX 5.75 and a 200 day moving average price of GBX 5.84.
OptiBiotix Health (LON:OPTI – Get Free Report) last released its quarterly earnings results on Thursday, September 17th. The company reported GBX (1.52) earnings per share for the quarter. OptiBiotix Health had a negative return on equity of 77.85% and a negative net margin of 332.69%.
About OptiBiotix Health
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
Featured Articles
- Five stocks we like better than OptiBiotix Health
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for OptiBiotix Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiBiotix Health and related companies with MarketBeat.com's FREE daily email newsletter.
